INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• The Promise Of Outcomes-Based Agreements For Cell & Gene Therapies

  There is a pressing need for stakeholders to find cost-effective ways to help more patients gain access to cell and gene therapies. While many types of innovative payment models exist, outcomes-based agreements — in which manufacturers and payers agree to specific performance and outcome metrics — are emerging as an attractive best practice option for both parties.

• Considerations For Cell Therapy Development And Manufacturing

  Review the latest methodologies, common practices, resources, applications and more to support every step of your cell therapy manufacturing workflow.

• How Terumo Blood And Cell Technologies' Are Advancing Cell and Gene Therapies

  Learn more about the to development of patient-centric innovations to help revolutionize health care and improve clinical outcomes.

• My Top Editorial Picks for 2022

  Fair warning, Cell & Gene readers. While this list includes some of my favorite editorial from 2022, it’s not even remotely close to being as extensive as I’d like. Why is that? Our library of content is so deep and so rich, I couldn’t possibly share and recap all of it with you in one article. Here are some highlights that helped to inform our readers about everything from process development to vendor selection to partnering with the right investment team.

• Leveraging Human Genetics To Advance Cell Therapies For Treatment Of Blood Cancers

  Leveraging human genetics data early in the drug discovery process to inform target prioritization is a powerful approach to mitigate risk and increase the likelihood of advancing safe therapies that make a transformative impact in patients’ lives.

• Successful Scaling Of Suspension-Based Viral Vector Production

  Explore this discussion amongst experts about how to develop robust, scalable, and cost-effective processes that yield high titers of high-quality viral vectors.

• How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing (Part 2)

  In the final part of the series, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio explain how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.

• How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing (Part 1)

  In part one of this two-part series, as seen in Life Science Leader magazine, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio weigh in on the understanding of how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.

• How Is A Slow Economy Helping Scaling Biotechs Find Space?

  Many biotech companies have begun subleasing excess space, giving smaller, scaling companies an opportunity to get the space they need with more flexible leases. Learn how these deals work.

• 6 Questions For A Successful Biotech Scaling Strategy

  Explore answers to key questions regarding how a real estate strategy can help you attract talent and adapt quickly to your changing business needs.